Safety of Interleukin Inhibitors in Psoriatic Patients with Latent Tuberculosis Infection Without Chemoprophylaxis: A Systematic Review
DOI:
https://doi.org/10.2340/actadv.v105.42081Keywords:
psoriasis, biologics, latent tuberculosis, infection, safetyAbstract
Current guidelines recommend psoriatic patients with latent tuberculosis infection undergo chemoprophylaxis prior to initiating any biologic. However, clinical studies indicate that interleukin (IL) inhibitors may not increase the risk of tuberculosis reactivation. This review evaluates the safety in psoriatic patients with latent tuberculosis infection using IL inhibitors without chemoprophylaxis. PubMed and EMBASE were searched up to 1 November 2024 in accordance with PRISMA. Fifteen studies, including one safety analysis of a clinical trial, 2 case series, and 12 retrospective studies were analysed. The included studies reported a total of 837 cases: 179 patients were treated with secukinumab, 69 with ixekizumab, 8 with brodalumab, 539 with risankizumab, 22 with guselkumab, and 20 with tildrakizumab. Psoriatic patients with latent tuberculosis infection using an IL-12/23 inhibitor without chemoprophylaxis were not found in this review. Three of the 837 cases exhibited reactivation of tuberculosis. The reactivation rate is 0.78% among psoriatic patients with latent tuberculosis infection using IL-17 inhibitors, and 0.17% among those using IL-23 inhibitors. Our analysis shows that IL-17 and IL-23 inhibitors do not increase the risk of tuberculosis activation in psoriatic patients with latent tuberculosis infection. The impact of IL-12/23 inhibitors on tuberculosis reactivation among psoriatic patients with latent tuberculosis infection remains uncertain and requires further investigation.
Downloads
References
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 205-212.
https://doi.org/10.1111/jdv.13854 DOI: https://doi.org/10.1111/jdv.13854
Zhang Z, Fan W, Yang G, Xu Z, Wang J, Cheng Q et al. Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2017; 7: e012567.
https://doi.org/10.1136/bmjopen-2016-012567 DOI: https://doi.org/10.1136/bmjopen-2016-012567
Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford) 2014; 53: 1872-1885.
https://doi.org/10.1093/rheumatology/keu172 DOI: https://doi.org/10.1093/rheumatology/keu172
4 . Torres T, Chiricozzi A, Puig L, Lé AM, Marzano AV, Dapavo P et al. Treatment of psoriasis patients with latent tuberculosis using IL-17 and IL-23 Inhibitors: A Retrospective, multinational, multicentre study. Am J Clin Dermatol 2024; 25: 333-342.
https://doi.org/10.1007/s40257-024-00845-4 DOI: https://doi.org/10.1007/s40257-024-00845-4
Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections. J Am Acad Dermatol. 2019; 80: 43-53.
https://doi.org/10.1016/j.jaad.2018.06.056 DOI: https://doi.org/10.1016/j.jaad.2018.06.056
Ribero S, Licciardello M, Quaglino P, Dapavo P. Efficacy and safety of secukinumab in patients with plaque psoriasis and latent tuberculosis. Case Rep Dermatol 2019; 11: 23-28.
https://doi.org/10.1159/000501989 DOI: https://doi.org/10.1159/000501989
Shu D, Zhang Z, Zhou EY, Ma X, Zhao Y. Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving IL-17 inhibitors? A cohort study. Dermatol Ther 2020; 33: e14512.
https://doi.org/10.1111/dth.14512 DOI: https://doi.org/10.1111/dth.14512
Machado Á, Abreu M, Torres T. Safety of secukinumab in psoriasis patients with latent tuberculosis infection. Eur J Dermatol 2020; 30: 740-741.
https://doi.org/10.1684/ejd.2020.3909 DOI: https://doi.org/10.1684/ejd.2020.3909
Megna M, Patruno C, Bongiorno MR, Gambardella A, Guarneri C, Foti C, et al. Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection. J Dermatolog Treat 2022; 33: 2629-2633.
https://doi.org/10.1080/09546634.2022.2062280 DOI: https://doi.org/10.1080/09546634.2022.2062280
Mastorino L, Dapavo P, Trunfio M, Avallone G, Rubatto M, Calcagno A, et al. Risk of reactivation of latent tuberculosis in psoriasis patients on biologic therapies: a retrospective cohort from a tertiary care centre in northern Italy. Acta Derm Venereol 2022; 102: adv00821.
https://doi.org/10.2340/actadv.v102.1982 DOI: https://doi.org/10.2340/actadv.v102.1982
Xiao Y, Mi W, Wang J, Wen D, Wang Y, Gu Y, et al. A propensity score-matched study on the changes of TB status and TB-IGRA values in patients with psoriasis with latent TB receiving secukinumab. Dermatol Ther (Heidelb) 2023; 13: 2387-2401.
https://doi.org/10.1007/s13555-023-00998-w DOI: https://doi.org/10.1007/s13555-023-00998-w
Yuan L, Li Y, Lin J, Lin X, Yang B, Man MQ, et al. Safety of biologics for psoriatic patients with latent tuberculosis. Clin Cosmet Investig Dermatol 2023; 16: 2333-2336.
https://doi.org/10.2147/CCID.S426253 DOI: https://doi.org/10.2147/CCID.S426253
Manzanares N, Vilarrasa E, López A, Alonso ML, Velasco M, Riera J, et al. No tuberculosis reactivations in psoriasis patients initiating new generation biologics despite untreated latent tuberculosis infection: Multicenter case series of 35 patients. J Eur Acad Dermatol Venereol 2024; 38: e26-e28.
https://doi.org/10.1111/jdv.19406 DOI: https://doi.org/10.1111/jdv.19406
He CX, Wu C, Zhang L, Jin HZ. Interleukin-17A inhibitors in patients with psoriasis and tuberculosis infection: a 2-year prospective study on safety without preventive treatment. Dermatol Ther (Heidelb) 2024; 14: 893-906.
https://doi.org/10.1007/s13555-024-01130-2 DOI: https://doi.org/10.1007/s13555-024-01130-2
Raimondo A, Amerio P, Balato A, Cusano F, Fargnoli M, Guarneri C, et al. Risankizumab efficacy and safety in psoriatic patients with latent tuberculosis infection: A multicentric real-world study. J Eur Acad Dermatol Venereol 2024 Sep 13 [online ahead of print].
https://doi.org/10.1111/jdv.20341 DOI: https://doi.org/10.1111/jdv.20341
Ibba L, Gargiulo L, Vignoli CA, Fiorillo G, Valenti M, Costanzo A, et al. Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study. J Dermatolog Treat 2023; 34: 2241585.
https://doi.org/10.1080/09546634.2023.2241585 DOI: https://doi.org/10.1080/09546634.2023.2241585
Zhao Z, Mu Z, Zhao Y, Zhang J, Cai L. Efficacy, drug survival, safety and metabolic parameters of ixekizumab in patients with moderate-to-severe psoriasis in China: A two-year real-world study. Int Immunopharmacol 2024; 143:113474.
https://doi.org/10.1016/j.intimp.2024.113474 DOI: https://doi.org/10.1016/j.intimp.2024.113474
Galluzzo M, D'Adamio S, Silvaggio D, Lombardo P, Bianchi L, Talamonti M. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opin Biol Ther 2020; 20 :173-182.
https://doi.org/10.1080/14712598.2020.1708897 DOI: https://doi.org/10.1080/14712598.2020.1708897
Gordon KB, Blauvelt A, Bachelez H, Coates LC, Van den Bosch FE, Kaplan B, et al. Long-term safety of risankizumab in patients with psoriatic disease: a comprehensive analysis from clinical trials. Dermatol Ther (Heidelb) 2024;14: 2523-2538.
https://doi.org/10.1007/s13555-024-01238-5 DOI: https://doi.org/10.1007/s13555-024-01238-5
World Health Organization. Global tuberculosis report 2021[EB/OL].
WHO consolidated guidelines on tuberculosis. Module 1: prevention - tuberculosis preventive treatment, second edition. Geneva: World Health Organization; 2024.
Mastorino L, Roccuzzo G, Dapavo P, Siliquini N, Avallone G, Rubatto M et al. Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult-to-treat population. Br J Dermatol 2022; 187: 263-265.
https://doi.org/10.1111/bjd.21048 DOI: https://doi.org/10.1111/bjd.21048
Viola R, Mastorino L, Megna M, Damiani G, Gisondi P, Argenziano G, et al. Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort. Int J Dermatol 2024; 63:351-358.
https://doi.org/10.1111/ijd.17005 DOI: https://doi.org/10.1111/ijd.17005
Lowe DM, Redford PS, Wilkinson RJ, O'Garra A, Martineau AR. Neutrophils in tuberculosis: friend or foe? Trends Immunol 2012; 33: 14-25.
https://doi.org/10.1016/j.it.2011.10.003 DOI: https://doi.org/10.1016/j.it.2011.10.003
Okamoto Yoshida Y, Umemura M, Yahagi A, O'Brien RL, Ikuta K, Kishihara K, et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 2010; 184: 4414-4422.
https://doi.org/10.4049/jimmunol.0903332 DOI: https://doi.org/10.4049/jimmunol.0903332
Kammüller M, Tsai TF, Griffiths CE, Kapoor N, Kolattukudy PE, Brees D, et al. Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin Transl Immunology 2017; 6: e152.
https://doi.org/10.1038/cti.2017.34 DOI: https://doi.org/10.1038/cti.2017.34
Elewski BE, Baddley JW, Deodhar AA, Magrey M, Rich PA, Soriano ER, et al. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. JAMA dermatology 2021; 157: 43-51.
https://doi.org/10.1001/jamadermatol.2020.3257 DOI: https://doi.org/10.1001/jamadermatol.2020.3257
Papp KA, Bachelez H, Blauvelt A, Winthrop KL, Romiti R, Ohtsuki M, et al. Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. Br J Dermatol 2017; 177: 1537-1551.
https://doi.org/10.1111/bjd.15723 DOI: https://doi.org/10.1111/bjd.15723
Ardain A, Domingo-Gonzalez R, Das S, Kazer SW, Howard NC, Singh A, et al. Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis. Nature 2019; 570: 528-532.
https://doi.org/10.1038/s41586-019-1276-2 DOI: https://doi.org/10.1038/s41586-019-1276-2
Khader SA, Pearl JE, Sakamoto K, Gilmartin L, Bell GK, Jelley-Gibbs DM, et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol 2005; 175: 788-795.
https://doi.org/10.4049/jimmunol.175.2.788 DOI: https://doi.org/10.4049/jimmunol.175.2.788
Huang YW, Tsai TF. A drug safety evaluation of risankizumab for psoriasis. Expert Opin Drug Saf 2020; 19: 395-402.
https://doi.org/10.1080/14740338.2020.1736034 DOI: https://doi.org/10.1080/14740338.2020.1736034
Wechter T, Cline A, Feldman SR. Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab. Ther Clin Risk Manag 2018; 14: 1489-1497.
https://doi.org/10.2147/TCRM.S177127 DOI: https://doi.org/10.2147/TCRM.S177127
Blauvelt A, Reich K, Papp KA, Kimball AB, Gooderham M, Tyring SK, et al. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. Br J Dermatol 2018; 179: 615-622.
https://doi.org/10.1111/bjd.16724 DOI: https://doi.org/10.1111/bjd.16724
Filipe-Santos O, Bustamante J, Chapgier A, Vogt G, de Beaucoudrey L, Feinberg J, et al. Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol 2006; 18: 347-361.
https://doi.org/10.1016/j.smim.2006.07.010 DOI: https://doi.org/10.1016/j.smim.2006.07.010
Tsai TF, Ho V, Song M, Szapary P, Kato T, Wasfi Y, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol 2012; 167: 1145-1152.
https://doi.org/10.1111/j.1365-2133.2012.11142.x DOI: https://doi.org/10.1111/j.1365-2133.2012.11142.x
Reactivation of latent tuberculosis on ustekinumab treatment for psoriasis: A case of tuberculosis peritonitis. Br J Dermatol 2016; 175: Supplement 1.
Tsai TF, Chiu HY, Song M, Chan D. A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial. Br J Dermatol 2013; 168: 444-446.
https://doi.org/10.1111/j.1365-2133.2012.11162.x DOI: https://doi.org/10.1111/j.1365-2133.2012.11162.x
Errichetti E, Piccirillo A. Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, despite isoniazid chemoprophylaxis. Eur J Dermatol 2014; 24: 508-509.
https://doi.org/10.1684/ejd.2014.2386 DOI: https://doi.org/10.1684/ejd.2014.2386
Koo T, Baek G, Jue MS. Risk of tuberculosis infection and serial changes in interferon-gamma release assays in elderly patients with psoriasis receiving biologic therapy. J Dermatol 2022; 49: 887-894.
https://doi.org/10.1111/1346-8138.16471 DOI: https://doi.org/10.1111/1346-8138.16471
Torres T, Brembilla NC, Langley RG, Warren RB, Thaçi D, Kolios AGA, et al. Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN-FRT expert consensus. J Eur Acad Dermatol Venereol 2025; 39: 52-69.
https://doi.org/10.1111/jdv.20287 DOI: https://doi.org/10.1111/jdv.20287
Additional Files
Published
How to Cite
License
Copyright (c) 2025 Jiaying Li, Xin Xiang, Zhaoyang Wang, Chaoyang Miao, Yunliu Chen, Zigang Xu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
